Devin Blankinship, MD
Cardiovascular Disease · Charleston, SCNPI 1255780854
Payments from drug & device makers
Across 243 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$905
- Abbott$713
- Philips North America LLC$709
- Medtronic$460
- E.r. Squibb & Sons, L.L.C.$450
- Boehringer Ingelheim$326
- plus $4K from 32 others
What the payments were for
- Consulting fees$3705%
- Food & beverage$6,66093%
- Education$1272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $905 |
| Abbott | 10 | $713 |
| Philips North America LLC | 17 | $709 |
| Medtronic | 5 | $460 |
| E.r. Squibb & Sons, L.L.C. | 18 | $450 |
| Boehringer Ingelheim | 15 | $326 |
| Amgen | 18 | $317 |
| Johnson & Johnson | 11 | $305 |
| Novo Nordisk | 10 | $286 |
| Scpharmaceuticals Inc. | 8 | $270 |
| Pfizer | 13 | $244 |
| Boston Scientific | 6 | $221 |
| Novartis | 11 | $207 |
| Esperion Therapeutics, Inc. | 8 | $156 |
| AstraZeneca | 3 | $153 |
| Edwards Lifesciences | 1 | $148 |
| Alnylam Pharmaceuticals Inc. | 5 | $147 |
| Heartflow, Inc. | 5 | $137 |
| Cardiva Medical, Inc. | 6 | $135 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $113 |
| Bridgebio Pharma, Inc. | 5 | $107 |
| Atricure, Inc. | 3 | $106 |
| Merck | 4 | $86 |
| Shockwave Medical, Inc | 2 | $62 |
| Biotronik Inc. | 1 | $55 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Cvrx, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (3126) ECC Solutions$187
- SAPIEN 3 Ultra RESILIA$148
- AMPLATZER AMULET$140
- CARDIOMEMS$139
- XARELTO$137
- CardioMEMS HF System$136
- (5091) Amb Mon & Diag Und$133
- WATCHMAN FLX$130
- FUROSCIX$119
- WAINUA$118
- ENSITE PRECISION$114
How this compares
$7,157 in reported general payments places this provider in the 60th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 199 | $218,736 |
| JardianceEmpagliflozin | 43 | $53,492 |
| XareltoRivaroxaban | 33 | $25,720 |
| Repatha SureclickEvolocumab | 19 | $19,515 |
| EntrestoSacubitril/Valsartan | 15 | $14,472 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $11,725 |
| FarxigaDapagliflozin Propanediol | 11 | $8,189 |
| Rosuvastatin Calcium | 149 | $1,825 |
| Ezetimibe | 58 | $1,750 |
| Metoprolol Succinate | 128 | $1,566 |
| Atorvastatin Calcium | 116 | $1,538 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 55 | $1,529 |
| Bumetanide | 23 | $892 |
| Propranolol Hcl | 30 | $615 |
| Spironolactone | 68 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $244 | $218,736199 claims |
| Boehringer IngelheimJardiance | $326 | $53,49243 claims |
| Johnson & JohnsonXarelto | $305 | $25,72033 claims |
| NovartisEntresto | $207 | $14,47215 claims |
| Esperion Therapeutics, Inc.Nexlizet | $156 | $11,72512 claims |
| AstraZenecaFarxiga | $153 | $8,18911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Charleston
- Robert BiedermanCharleston$801K
- William YarbroughCharleston$231K
- Terrence O BrienCharleston$160K
- Ashley WaringCharleston$137K
- Priyanka BhattacharyaCharleston$107K
- Geetha PintoCharleston$93K
- Pamela MorrisCharleston$85K
- James SmithCharleston$64K
- William EdwardsCharleston$40K
- Ian LaxinaCharleston$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.